Cargando…
Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956669/ https://www.ncbi.nlm.nih.gov/pubmed/33668689 http://dx.doi.org/10.3390/molecules26051213 |
_version_ | 1783664489399320576 |
---|---|
author | Lainetti, Patrícia F. Leis-Filho, Antonio F. Kobayashi, Priscila E. de Camargo, Laíza S. Laufer-Amorim, Renee Fonseca-Alves, Carlos E. Souza, Fabiana F. |
author_facet | Lainetti, Patrícia F. Leis-Filho, Antonio F. Kobayashi, Priscila E. de Camargo, Laíza S. Laufer-Amorim, Renee Fonseca-Alves, Carlos E. Souza, Fabiana F. |
author_sort | Lainetti, Patrícia F. |
collection | PubMed |
description | Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC(50). Then, cell lines were treated with rapamycin IC(50) dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC(50) dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC(50) were higher when compared to other studies. |
format | Online Article Text |
id | pubmed-7956669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79566692021-03-16 Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro Lainetti, Patrícia F. Leis-Filho, Antonio F. Kobayashi, Priscila E. de Camargo, Laíza S. Laufer-Amorim, Renee Fonseca-Alves, Carlos E. Souza, Fabiana F. Molecules Article Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC(50). Then, cell lines were treated with rapamycin IC(50) dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC(50) dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC(50) were higher when compared to other studies. MDPI 2021-02-25 /pmc/articles/PMC7956669/ /pubmed/33668689 http://dx.doi.org/10.3390/molecules26051213 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lainetti, Patrícia F. Leis-Filho, Antonio F. Kobayashi, Priscila E. de Camargo, Laíza S. Laufer-Amorim, Renee Fonseca-Alves, Carlos E. Souza, Fabiana F. Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title | Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title_full | Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title_fullStr | Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title_full_unstemmed | Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title_short | Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro |
title_sort | proteomics approach of rapamycin anti-tumoral effect on primary and metastatic canine mammary tumor cells in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956669/ https://www.ncbi.nlm.nih.gov/pubmed/33668689 http://dx.doi.org/10.3390/molecules26051213 |
work_keys_str_mv | AT lainettipatriciaf proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT leisfilhoantoniof proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT kobayashipriscilae proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT decamargolaizas proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT lauferamorimrenee proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT fonsecaalvescarlose proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro AT souzafabianaf proteomicsapproachofrapamycinantitumoraleffectonprimaryandmetastaticcaninemammarytumorcellsinvitro |